Title: Clinical study on Kanglaite combined with Tegafur, Gimeracil and Oteracil Potassium in treatment of elderly patients with advanced colorectal cancer
Abstract: Objective To investigate the efficacy and safety of Kanglaite combined with Tegafur, Gimeracil and Oteracil Potassium in treatment of elderly patients with advanced colorectal cancer. Methods Elderly patients(88 cases) with advanced colorectal cancer who came to the Fourth People's Hospital of Shenyang from January 2011 to April 2014 were randomly divided into the control and treatment groups, and each group had 44 cases. The patients in control group were given Tegafur, Gimeracil and Oteracil Potassium Capsule single-agent therapy. The patients in the treatment group were iv administered with Kanglaite Injection at the basis of control group, beginning on the first day of 200 m L/d for 21 d, and withdrawal 21 d. Six weeks were as one course of treatment, and two groups were treated for two courses. The clinical efficacy, toxic effects, life quality and immune function in two groups were evaluated. Results After treatment, the total effective rate of control group was 18.18%, and the clinical benefit rate was 56.82%, while the total effective rate of treatment group was 29.55%, and the clinical benefit rate was 79.55%, and there were differences between the two groups(P 0.05). The incidences of gastrointestinal reaction, inflammation of the oral mucosa and hematology toxicity in the treatment group were lower than those in the control group, and there were differences between the two groups(P 0.05). The life quality effectiveness in control and treatment group were 34.09% and 56.82%, respectively, and there were differences between the two groups(P 0.05). After treatment, numbers of CD3+, CD4+, CD4+/CD8+ and NK cell in the treatment group were increased, and the level of CD8+ cell was lower, and the difference was statistically significant in the same group before and after treatment(P 0.05). After treatment, CD3+, CD4+, NK, and CD4+/CD8+ cell in the treatment group were more than those in the control group, while the level of CD8 cells was lower than that in the control group, and there were differences between the two groups(P 0.05). Conclusion Kanglaite combined with Tegafur, Gimeracil and Oteracil Potassium has the good clinical effect in treatment of elderly patients with advanced colorectal cancer, and can improve the quality of life and immune function, while can reduce the adverse reaction of chemotherapy, which is worth clinical promotion.
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot